Vaccine study for high-risk smoldering or myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 trial tests a cancer vaccine (TG01/QS-21) in people with high-risk smoldering multiple myeloma or multiple myeloma. It aims to see how safe the vaccine is and whether it can help the immune system control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older and able to sign informed consent.
- Your test must show a specific RAS gene change (KRAS or NRAS at codon 12 or 13).
- You must have either high-risk smoldering multiple myeloma (SMM) or multiple myeloma (MM) with measurable disease.
- For high-risk SMM, your screening blood/bone-marrow results must meet at least 2 of these: high M-protein, a high light-chain ratio, and/or high bone-marrow plasma cells.
- If you had a stem cell transplant, you must be at least 3 months past it and have tried lenalidomide maintenance for at least 2 cycles (in certain situations).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.